Data suggest stronger immune fitness in earlier lines may be associated with longer progression-free survival2 BEERSE, BELGIUM, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced ...
EPCORE® DLBCL-3 Trial Results Separately, new results from the ongoing Phase 2 EPCORE DLBCL-3 trial (abstract 63), for fixed-duration epcoritamab monotherapy in newly diagnosed elderly patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback